Neostigmine Methylsulfate Injection — FDA Drug Shortage

To Be Discontinued — Fresenius Kabi USA, LLC

The FDA lists a drug shortage record for Neostigmine Methylsulfate Injection (injection) from Fresenius Kabi USA, LLC with status To Be Discontinued. The shortage was first posted on Jan 12, 2026.

Shortage details

Status
To Be Discontinued
Company
Fresenius Kabi USA, LLC
Package NDC
63323-413-10
Dosage Form
Injection
Presentation
Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)
Initial Posting
Jan 12, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.